SET and acute myeloid leukemia: Next, we treated AML cells with either CX-4945 or CK2 siRNA, and found that CK2 inhibition or downregulation resulted in increased nuclear and decreased cytoplasmic localization of SET (Fig. 5a, b, Supplementary Fig. S8b, c), which increased PP2A activity (Fig. 5c).